REPCF

Healthcare Biotechnology

0913693 B.C. Ltd.

$0.00

-0.00 -0.00% today

Price History

Not enough data

Key Stats

Market Cap

7,357.781

Avg Volume

929

EPS

-$0.01

52W High

$0.04

52W Low

$0.00

Div. Yield

0.0%

Valuation

P/B Ratio

-0.00

P/S Ratio

0.02

EV/Revenue

3.18

Margins

Gross Margin 100.0%

Operating Margin 62.0%

Net Margin (88.7%)

EBITDA Margin 0.0%

Growth & Returns

Revenue Growth (YoY)

0.0%

Return on Assets

445.5%

Liquidity & Leverage

Current Ratio

0.02

Quick Ratio

0.02

Total Cash

5,501

Total Debt

1.12M

About

0913693 B.C. Ltd., a regenerative medicine company, develops autologous cell therapies for the treatment of functional cellular deficits. Its treatments use autologous cell therapy to treat chronic tendon injuries, androgenetic alopecia, and skin aging by restoring cellular function to rejuvenate aging or sun damaged skin, regrow hair, and repair tendons. The company's product candidates include RCH-01, a cell therapy for pattern baldness; RCS-01, a cell therapy for aging or sun damaged skin; and RCT-01, a cell therapy for tendon degeneration. It is also involved in the developing DermaPrecise, a dermal injection device. 0913693 B.C. Ltd. has a licensing and collaborative agreement with YOFOTO (China) Health Industry Co. Ltd. to develop and commercialize programs. The company was formerly known as RepliCel Life Sciences Inc. and changed its name to 0913693 B.C. Ltd. in March 2025. 0913693 B.C. Ltd. is based in Vancouver, Canada.